Literature DB >> 11748208

Growth phase influences complement resistance of Bordetella pertussis.

Michael G Barnes1, Alison A Weiss.   

Abstract

The BrkA protein of Bordetella pertussis inhibits killing by the antibody-dependent classical pathway of complement; however, susceptibility to complement can be highly variable. Log-phase bacteria grown in Stainer-Scholte (SS) broth plated on Bordet-Gengou (BG) agar were about 500 times more sensitive to killing by complement than stationary-phase SS-BG cultures. While always more susceptible to complement than the wild-type strain, a BrkA mutant displayed a similar growth phase variation in susceptibility to complement. Growth phase susceptibility to complement was also observed for a mutant constitutive for Bvg activation of BrkA, suggesting that modulation of virulence factor expression was not responsible for sensitivity to complement. Susceptibility was not due to differential antigenic expression, since serum adsorbed with complement-resistant, stationary-phase SS-BG cultures lacked bactericidal activity against B. pertussis harvested at all times during the growth cycle. These results suggest that log-phase susceptibility to complement is not due to variable expression of BrkA or antigenic differences and may be an inherent property of rapidly growing cultures. Implications for vaccine development are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11748208      PMCID: PMC127634          DOI: 10.1128/IAI.70.1.403-406.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

Review 1.  Complement-mediated killing of susceptible gram-negative bacteria: an elusive mechanism.

Authors:  P W Taylor
Journal:  Exp Clin Immunogenet       Date:  1992

2.  Adenylate cyclase toxin is critical for colonization and pertussis toxin is critical for lethal infection by Bordetella pertussis in infant mice.

Authors:  M S Goodwin; A A Weiss
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

3.  Serum resistance in bvg-regulated mutants of Bordetella pertussis.

Authors:  R C Fernandez; A A Weiss
Journal:  FEMS Microbiol Lett       Date:  1998-06-01       Impact factor: 2.742

4.  Environmental regulation of expression of virulence determinants in Bordetella pertussis.

Authors:  A R Melton; A A Weiss
Journal:  J Bacteriol       Date:  1989-11       Impact factor: 3.490

5.  Cloning and sequencing of a Bordetella pertussis serum resistance locus.

Authors:  R C Fernandez; A A Weiss
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

6.  How complement kills E. coli. I. Location of the lethal lesion.

Authors:  S D Wright; R P Levine
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

7.  Tn5-induced mutations affecting virulence factors of Bordetella pertussis.

Authors:  A A Weiss; E L Hewlett; G A Myers; S Falkow
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

Review 8.  Understanding signal transduction during bacterial infection.

Authors:  B J Akerley; J F Miller
Journal:  Trends Microbiol       Date:  1996-04       Impact factor: 17.079

9.  Constitutive sensory transduction mutations in the Bordetella pertussis bvgS gene.

Authors:  J F Miller; S A Johnson; W J Black; D T Beattie; J J Mekalanos; S Falkow
Journal:  J Bacteriol       Date:  1992-02       Impact factor: 3.490

10.  Characterization of human bactericidal antibodies to Bordetella pertussis.

Authors:  A A Weiss; P S Mobberley; R C Fernandez; C M Mink
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

View more
  7 in total

1.  Opsonophagocytic activity and other serological indications of Bordetella pertussis infection in military recruits in Norway.

Authors:  Audun Aase; Tove Karin Herstad; Samuel Merino; Kari Torkildsen Brandsdal; Bjørn Peter Berdal; Erja M Aleksandersen; Ingeborg S Aaberge
Journal:  Clin Vaccine Immunol       Date:  2007-05-16

2.  Bordetella pertussis acquires resistance to complement-mediated killing in vivo.

Authors:  Elizabeth J Pishko; David J Betting; Christina S Hutter; Eric T Harvill
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

3.  Bordetella pertussis autotransporter Vag8 binds human C1 esterase inhibitor and confers serum resistance.

Authors:  Nico Marr; Nita R Shah; Rose Lee; Emma J Kim; Rachel C Fernandez
Journal:  PLoS One       Date:  2011-06-14       Impact factor: 3.240

4.  Bordetella pertussis isolates vary in their interactions with human complement components.

Authors:  Charlotte Brookes; Irene Freire-Martin; Breeze Cavell; Frances Alexander; Stephen Taylor; Ruby Persaud; Norman Fry; Andrew Preston; Dimitri Diavatopoulos; Andrew Gorringe
Journal:  Emerg Microbes Infect       Date:  2018-05-09       Impact factor: 7.163

5.  Development and Standardization of a High-Throughput Bordetella pertussis Growth-Inhibition Assay.

Authors:  Anaïs Thiriard; Dominique Raze; Camille Locht
Journal:  Front Microbiol       Date:  2020-04-23       Impact factor: 5.640

6.  Humanised monoclonal antibodies neutralise pertussis toxin by receptor blockade and reduced retrograde trafficking.

Authors:  Edith Acquaye-Seedah; Yimin Huang; Jamie N Sutherland; Andrea M DiVenere; Jennifer A Maynard
Journal:  Cell Microbiol       Date:  2018-09-23       Impact factor: 3.715

7.  Polymerization of C9 enhances bacterial cell envelope damage and killing by membrane attack complex pores.

Authors:  Dennis J Doorduijn; Dani A C Heesterbeek; Maartje Ruyken; Carla J C de Haas; Daphne A C Stapels; Piet C Aerts; Suzan H M Rooijakkers; Bart W Bardoel
Journal:  PLoS Pathog       Date:  2021-11-09       Impact factor: 7.464

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.